Sort
10,766 grants matching “checkpoint inhibitor”
Impact of CREB-driven mechanism in shaping the tumor-immune landscape
$324,760Nagaraj S. Nagathihalli · University Of Miami School Of Medicine · R01 · FY2023 · CA
Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy
$324,675Gaddiel Galarza-Munoz · Autoimmunity Biologic Solutions, Inc. · R43 · FY2021 · CA
Targeting EphB4-ephrinB2 to decrease immunosuppression in HNSCC
$324,670Sana D Karam · University Of Colorado Denver · P50 · FY2023 · CA
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
$324,587Douglas G McNeel · University Of Wisconsin-Madison · P01 · FY2020 · CA
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
$324,561Arlene H Sharpe · Harvard Medical School · U54 · FY2019 · CA
Investigating multifactorial beta-catenin activation in hepatocellular cancers
$324,555Xin Chen · University Of Hawaii At Manoa · R01 · FY2022 · CA
E2A/HEB TRANSCRIPTION FACTORS IN T CELL DEVELOPMENT
$324,324Yuan Zhuang · Duke University · R01 · FY2010 · GM
Stinging the Glioma Immune Landscape
$324,017Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2023 · NS
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy
$324,002Jennifer D Wu · Northwestern University At Chicago · P50 · FY2021 · CA
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1
$323,950Leif W Ellisen · Massachusetts General Hospital · R01 · FY2010 · CA
Metabolic reprogramming of the tumor microenvironment and therapy resistance
$323,925Ernst Lengyel · University Of Chicago · R35 · FY2021 · CA
ATM as target for malignant glioma radiosensitization.
$323,762Kristoffer Valerie · Virginia Commonwealth University · R01 · FY2010 · NS
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
$323,587Catherine T Flores · University Of Florida · R01 · FY2024 · NS
The Role of AKT in Prostate Cancer
$323,496William R Sellers · Beth Israel Deaconess Medical Center · P01 · FY2011 · CA
Mechanism of ultraviolet radiation induced immune tolerance
$323,433Hui Xu · University Of Alabama At Birmingham · R01 · FY2022 · AR
A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations
$323,297Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2025 · CA
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
$323,272Jean Zhao · Brigham And Women'S Hospital · P50 · FY2019 · CA
Targeting EphB4-ephrinB2 to decrease immunosuppression in HNSCC
$323,204Sana D Karam · University Of Colorado Denver · P50 · FY2024 · CA
Effects of ATR-CHK1 inhibition on genome stability and cancer progression
$323,192Eric J Brown · University Of Pennsylvania · R01 · FY2018 · CA
ATM as target for malignant glioma radiosensitization.
$323,135Kristoffer Valerie · Virginia Commonwealth University · R01 · FY2009 · NS
Project 1
$323,023Mark M. Awad · Dana-Farber Cancer Inst · P50 · FY2023 · CA
The MRAD9 Radioresistance Gene
$323,004Howard B Lieberman · Columbia University Health Sciences · R01 · FY2013 · GM
Impact of Irreversible T Cell Dysfunction on Transplant Outcomes
$323,000Wenhao Chen · Methodist Hospital Research Institute · R56 · FY2024 · AI
Core 1: Mouse Model and Tissue Biobank Core
$322,871Roger S Lo · Institute For Systems Biology · U54 · FY2022 · CA
Study of Anti-Survival signals in NF1
$322,663Changyan Chen · Northeastern University · R01 · FY2016 · CA